Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Teriflunomide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH known ✓ | Q02127 | 8/20 | 0.72 |
| ▸ | RAB9A | P51151 | 4/20 | 0.72 |
| ▸ | NPC1 | O15118 | 3/20 | 0.72 |
| ▸ | GMNN | O75496 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | TP53 | P04637 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | HTR1A | P08908 | 1/20 | 0.72 |
| ▸ | THRB | P10828 | 1/20 | 0.72 |
| ▸ | PIM1 | P11309 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | MAOA | P21397 | 1/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.72 |
| ▸ | HTR2A | P28223 | 1/20 | 0.72 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.72 |
| ▸ | CCKBR | P32239 | 1/20 | 0.72 |
| ▸ | MC4R | P32245 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | THPO | P40225 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leflunomide SCHEMBL7650952 | 0.90 | DHODH (0.61) | DHODHRAB9ANPC1GMNNLMNA | |
| SCHEMBL24047619 | 0.88 | DHODH (0.64) | DHODHRAB9ANPC1GMNNLMNA | |
| Leflunomide SCHEMBL29271960 | 0.86 | RAB9A (0.92) | DHODHRAB9ANPC1GMNNLMNA | |
| Leflunomide SCHEMBL5057 | 0.85 | RAB9A (1.00) | DHODHRAB9ANPC1GMNNLMNA | |
| Leflunomide SCHEMBL1243495 | 0.85 | RAB9A (1.00) | DHODHRAB9ANPC1GMNNLMNA | |
| Teriflunomide SCHEMBL2760666 | 0.82 | DHODH (1.00) | DHODHRAB9ANPC1CYP1A2CYP3A4 | |
| Teriflunomide SCHEMBL22661 | 0.82 | DHODH (1.00) | DHODHRAB9ANPC1CYP1A2CYP3A4 | |
| Teriflunomide SCHEMBL20214092 | 0.82 | DHODH (1.00) | DHODHRAB9ANPC1CYP1A2CYP3A4 | |
| Teriflunomide SCHEMBL993119 | 0.82 | DHODH (1.00) | DHODHRAB9ANPC1CYP1A2CYP3A4 | |
| Teriflunomide SCHEMBL8466730 | 0.81 | DHODH (0.97) | DHODHRAB9ANPC1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2608782-B1 | NOVEL USE OF LEFLUNOMIDE AND MALONONITRILAMIDES | ALGIAX PHARMACEUTICALS GMBH (DE) | 2016-06-29 | — | — | EP | disclosed |
| US-8957098-B2 | Use of leflunomide and malononitrilamides | ALGIAX PHARMACEUTICALS GMBH (DE) | 2015-02-17 | — | — | US | disclosed |
| US-20130274301-A1 | Novel Use of Leflunomide and Malononitrilamides | AL-GIAX PHARMACEUTICALS GMBH (DE) | 2013-10-17 | — | — | US | disclosed |
| EP-2608782-A1 | NOVEL USE OF LEFLUNOMIDE AND MALONONITRILAMIDES | Algiax Pharmaceuticals GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012025217-A1 | NOVEL USE OF LEFLUNOMIDE AND MALONONITRILAMIDES | ALGIAX PHARMACEUTICALS GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274301-A1 | Novel Use of Leflunomide and Malononitrilamides | LEF1, TPMT, MALT1 | DHODH 218/4885RAB9A 4160/4885NPC1 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.